P1140 - The Efficacy of Subcutaneous Epcoritamab vs Standard-of-Care (SCHOLAR-5) in Patients with Relapsed/Refractory Follicular Lymphoma After ≥2 Systemic Therapies: An Indirect Treatment Comparison

Kim Linton; et al.

doi:10.1002/hem3.104

P1140 - The Efficacy of Subcutaneous Epcoritamab vs Standard-of-Care (SCHOLAR-5) in Patients with Relapsed/Refractory Follicular Lymphoma After ≥2 Systemic Therapies: An Indirect Treatment Comparison

Kim Linton, et al.

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	2077-2078
Journal	HemaSphere
Volume	18
Issue number	S1
DOIs	https://doi.org/10.1002/hem3.104
Publication status	Published - 14 Jun 2024
Event	European Hematology Association (EHA) Hybrid Congress 2024 - IFEMA MADRID RECINTO FERIAL (fairgrounds), Madrid, Spain Duration: 13 Jun 2024 → 16 Jun 2024 https://ehaweb.org/congress/eha2024-hybrid-congress/eha2024-hybrid-congress-4/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hem3.104Licence: CC BY-NC-ND

Cite this

@article{7205cb10cfb24c6d8483b7b2a1150277,

title = "P1140 - The Efficacy of Subcutaneous Epcoritamab vs Standard-of-Care (SCHOLAR-5) in Patients with Relapsed/Refractory Follicular Lymphoma After ≥2 Systemic Therapies: An Indirect Treatment Comparison",

author = "Kim Linton and {et al.}",

year = "2024",

month = jun,

day = "14",

doi = "10.1002/hem3.104",

language = "English",

volume = "18",

pages = "2077--2078",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Lippincott Williams & Wilkins",

number = "S1",

note = "European Hematology Association (EHA) Hybrid Congress 2024, EHA2024 Hybrid Congress ; Conference date: 13-06-2024 Through 16-06-2024",

url = "https://ehaweb.org/congress/eha2024-hybrid-congress/eha2024-hybrid-congress-4/",

}

TY - JOUR

T1 - P1140 - The Efficacy of Subcutaneous Epcoritamab vs Standard-of-Care (SCHOLAR-5) in Patients with Relapsed/Refractory Follicular Lymphoma After ≥2 Systemic Therapies: An Indirect Treatment Comparison

AU - Linton, Kim

AU - et al.,

PY - 2024/6/14

Y1 - 2024/6/14

U2 - 10.1002/hem3.104

DO - 10.1002/hem3.104

M3 - Meeting Abstract

SN - 2572-9241

VL - 18

SP - 2077

EP - 2078

JO - HemaSphere

JF - HemaSphere

IS - S1

T2 - European Hematology Association (EHA) Hybrid Congress 2024

Y2 - 13 June 2024 through 16 June 2024

ER -